Cortex gets OK to resume enrollment for Ampakine trials

(Reuters) - The study of Ampakine CX717, which was originally designed
with doses of 200mg, 600mg and 1200mg, was placed on hold by
the U.S. Food and Drug Administration due to concerns over some
preclinical animal data.





Read more at Reuters.com Government Filings News